Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology

Bio-Techne (NASDAQ: TECH) announced a strategic collaboration with the Wyss Center Geneva on Dec 11, 2025 to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) announced a strategic collaboration with the Wyss Center Geneva on Dec 11, 2025 to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens. The project aims to extend Bio-Techne's multiomic spatial biology capabilities from 2D into intact 3D samples, enabling high-resolution multiomic analysis in thicker sections.

The collaboration targets automation to reduce manual complexity, accelerate drug discovery and diagnostic development, and support New Approach Methodologies (NAMs) such as organoids and AI-driven predictive modeling to potentially reduce animal testing. Executives from both organizations cited the partnership as a step to broaden accessibility of spatial biology tools for preclinical research.

Argus Dec 11 session

-0.94% close to close Open Argus

Details

News Market Reaction – TECH

On Dec 11, the day this news came out, TECH closed 0.94% below the previous close.

Data tracked by StockTitan Argus for the Dec 11 session.

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   Product launch

   24h Move

   -2.4%

   Enhanced Leo System launch for higher-throughput multiplex protein analysis.

2. Nov 25

   Investor conferences

   24h Move

   +3.7%

   Announcement of three early-December healthcare investor conference presentations.

3. Nov 18

   AI licensing deal

   24h Move

   -0.8%

   Exclusive rights to AI-designed NovoBody Duo proteins expanding diagnostics portfolio.

4. Nov 06

   Investor conferences

   24h Move

   -2.9%

   Schedule of four November healthcare investor conference presentations.

5. Nov 05

   Earnings update

   24h Move

   -1.9%

   Q1 FY2026 results with slightly lower sales but higher margins and EPS.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

multiomics, spatial biology, organoids, rna, +2 more

6 terms

multiomics medical

"aims to automate RNA and protein detection in 3D tissue specimens"

Multiomics is the combined analysis of different biological data types — such as genes, proteins and small‑molecule chemicals — to build a complete picture of how cells or organisms function. For investors, multiomics matters because it can make drug and diagnostic development more precise and faster by revealing causes, predicting who will benefit from a therapy, and reducing downstream clinical trial surprises — like using multiple camera angles to better understand a complex scene.

spatial biology medical

"accelerate the broad adoption of spatial biology"

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

organoids medical

"through New Approach Methodologies (NAMs) such as organoids and predictive modeling"

Miniaturized, simplified versions of human organs grown in the lab from stem cells that mimic key structure and function of real tissues. Like scale models used by architects, organoids let researchers test drugs, study disease and predict how human tissues will respond without using whole patients, which can speed development, reduce costs and lower risk for investors evaluating biotech pipelines and therapies.

rna medical

"develop an automated workflow for simultaneous RNA and protein detection in 3D specimens"

RNA (ribonucleic acid) is a natural molecule that carries instructions from a cell’s DNA to make proteins and can also act as a tool to turn genes on or off; think of it as a messenger or software that tells biological machinery what to build or modify. It matters to investors because RNA-based tests and therapies can create new markets or change treatment costs and regulatory risk, so progress or setbacks in RNA science often drive valuation swings in biotech companies.

predictive modeling technical

"advancing organoid research and broader AI-driven predictive modeling"

Predictive modeling uses data and computer algorithms to estimate what is likely to happen next—like a weather forecast for business outcomes. By spotting patterns in past performance and current indicators, these models project sales, risks, customer behavior or other metrics that matter to investors. The results help investors weigh potential returns and risks, compare scenarios, and make more informed decisions faster than relying on intuition alone.

preclinical research medical

"has the potential to improve preclinical research by reducing reliance on animal testing"

Preclinical research is the stage of drug or medical-device development where scientists test a candidate in the lab and in animals to assess safety, dosing and whether it works before giving it to humans. For investors, this phase is like a prototype being tested in a workshop: positive preclinical results reduce the unknowns and can increase a project’s value, while failures or unclear data signal higher risk and longer timelines to any potential return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers.
  
  
• Innovation has the potential to improve preclinical research by reducing reliance on animal testing through New Approach Methodologies (NAMs) such as organoids and predictive modeling, enabling new directions and scale in advanced biomedical studies.
  
  
• Partnership underscores Bio-Techne's commitment to drive innovation and accelerate the broad adoption of spatial biology.

MINNEAPOLIS, Dec. 11, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a strategic collaboration between one of its spatial biology brands, Lunaphore, and the Wyss Center for Bio and Neuroengineering (Wyss Geneva) to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens. The project will enable high-resolution multiomic analysis within intact 3D samples.

Bio-Techne's current multiomic spatial biology technologies deliver unparalleled insights in 2D, enabling breakthroughs in disease research and therapeutic development. The Wyss initiative aims to extend these capabilities into 3D, unlocking an even deeper understanding of tissue structure and cellular interactions.

The partnership seeks to overcome the limitations of traditional approaches and manual processes, which often restrict the ability to capture the true complexity of biological systems. By automating multiomic analysis in 3D using thicker sections, this innovation has the potential to accelerate drug discovery, enhance diagnostic development, and reduce dependence on animal models by advancing organoid research and broader AI-driven predictive modeling, expanding both scientific progress and ethical research practices.

"3D multiomics will greatly enhance spatial insights gathering in the future, with the power to transform how we understand biology. However, to unlock its full impact, we must make it accessible to every researcher, everywhere. Partnering with Bio-Techne is an extraordinary opportunity to turn that ambition into reality," said Dr. Stéphane Pages, Director of Neuroimaging at Wyss Geneva.

"This collaboration reflects Bio-Techne's commitment to advancing spatial biology through meaningful partnerships and cutting-edge technology," said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne. "By combining our expertise in RNA and protein detection with Wyss Geneva's leadership in 3D translational research, we are enabling new possibilities in preclinical modeling and accelerating the path from discovery to impact."

The partnership expands Bio-Techne's broader strategy to make spatial biology technologies more accessible and foster innovation in life sciences and diagnostics. By lowering technical barriers and increasing analytical depth, the collaboration with Wyss Geneva positions Bio-Techne as a leader in next-generation research tools, enabling scientists to study biology in its actual spatial context.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

About Wyss Center for Bio and Neuroengineering
The Wyss Center for Bio and Neuroengineering (Wyss Geneva) is an independent, not-for-profit neuro venture builder based at Campus Biotech in Geneva. Combining expertise in AI, bioengineering, and neuroengineering, the Center develops technologies to restore neural functions and advance precision therapies for brain and mental health disorders. Founded in 2014 with the support of Swiss entrepreneur and philanthropist Hansjörg Wyss, the Center partners with ventures, academia, industry, and investors to accelerate neurotechnology innovation. Learn more on our website and follow us on social media.

Contact:

Corporate Communications
media.relations@bio-techne.com

David Clair, Vice President, Investor Relations
david.clair@bio-techne.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-partners-with-the-wyss-center-geneva-to-advance-automated-3d-multiomics-technology-and-accelerate-spatial-biology-302636825.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bio-Techne (TECH) and Wyss Geneva announce on December 11, 2025?

They announced a collaboration to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens to enable high-resolution multiomic analysis.

How could the TECH–Wyss Geneva partnership affect preclinical research and organoid studies?

The effort aims to automate 3D multiomics, which could accelerate preclinical modeling and support organoid research and AI-driven predictive modeling, potentially reducing reliance on animal testing.

Will the Bio-Techne (TECH) collaboration change current spatial biology capabilities?

Yes; the project intends to extend Bio-Techne's existing 2D multiomic technologies into intact 3D samples, increasing analytical depth and spatial context.

What are the stated goals for automation in the TECH and Wyss Geneva project?

The goals are to reduce manual complexity and technical barriers, enable multiomic analysis in thicker sections, and make spatial biology more accessible to researchers.

Does the announcement for TECH include financial terms or timelines?

No; the announcement describes technical collaboration objectives but does not provide financial details, timeline, or commercialization milestones.